BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26377037)

  • 21. Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course.
    Murakami S; Yokose T; Saito H; Sakuma Y; Matsukuma S; Hasegawa C; Kondo T; Oshita F; Ito H; Tsuboi M; Nakayama H; Kameda Y; Noda K; Yamada K
    Lung Cancer; 2010 Sep; 69(3):361-4. PubMed ID: 20659620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma.
    Jeong CJ; Lee HY; Han J; Jeong JY; Lee KS; Choi YL; Choi JY
    Clin Nucl Med; 2015 Jan; 40(1):e34-9. PubMed ID: 25243942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.
    Noonan SA; Patil T; Gao D; King GG; Thibault JR; Lu X; Bunn PA; Doebele RC; Purcell WT; Barón AE; Camidge DR
    J Thorac Oncol; 2018 Jan; 13(1):134-138. PubMed ID: 28843358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
    Takahashi T; Sonobe M; Kobayashi M; Yoshizawa A; Menju T; Nakayama E; Mino N; Iwakiri S; Sato K; Miyahara R; Okubo K; Manabe T; Date H
    Ann Surg Oncol; 2010 Mar; 17(3):889-97. PubMed ID: 20183914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
    Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
    Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma.
    Zhu J; Cai L; Yang H; Wen Y; Wang J; Rong T; Shao J; Zhang L
    Thorac Cancer; 2014 Sep; 5(5):411-6. PubMed ID: 26767032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations.
    Xu L; Lei J; Wang QZ; Li J; Wu L
    Genet Mol Res; 2015 Oct; 14(4):12973-83. PubMed ID: 26505450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.
    Yip PY; Yu B; Cooper WA; Selinger CI; Ng CC; Kennedy CW; Kohonen-Corish MR; McCaughan BC; Trent RJ; Boyer MJ; Kench JG; Horvath LG; O'Toole SA
    J Thorac Oncol; 2013 Apr; 8(4):408-14. PubMed ID: 23392229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and CT characteristics of surgically resected lung adenocarcinomas harboring ALK rearrangements or EGFR mutations.
    Wang H; Schabath MB; Liu Y; Han Y; Li Q; Gillies RJ; Ye Z
    Eur J Radiol; 2016 Nov; 85(11):1934-1940. PubMed ID: 27776643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Driven Gene in Patients with Lung Squamous Cell Carcinoma: 
Analysis of Clinicopathologic Characteristics and Prognosis].
    Zhang T; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):648-652. PubMed ID: 27760592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
    Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
    Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
    J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adequacy of CT-guided biopsies with histomolecular subtyping of pulmonary adenocarcinomas: influence of ATS/ERS/IASLC guidelines.
    Ferretti GR; Busser B; de Fraipont F; Reymond E; McLeer-Florin A; Mescam-Mancini L; Moro-Sibilot D; Brambilla E; Lantuejoul S
    Lung Cancer; 2013 Oct; 82(1):69-75. PubMed ID: 23927885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Asymptomatic pulmonary embolism in lung cancer: prevalence and analysis of clinical and radiological characteristics in 141 outpatients.
    Tiseo M; Bersanelli M; Pesenti Barili M; Bartolotti M; De Luca G; Gelsomino F; Camisa R; Cademartiri F; Ardizzoni A
    Tumori; 2012; 98(5):594-600. PubMed ID: 23235754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rare discrepancies in a driver gene alteration within histologically heterogeneous primary lung cancers.
    Zhong WZ; Su J; Xu FP; Zhai HR; Zhang XC; Yang XN; Chen ZY; Chen ZH; Li W; Dong S; Zhou Q; Yang JJ; Liu YH; Wu YL
    Lung Cancer; 2015 Nov; 90(2):205-11. PubMed ID: 26391021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene.
    Fukui T; Yatabe Y; Kobayashi Y; Tomizawa K; Ito S; Hatooka S; Matsuo K; Mitsudomi T
    Lung Cancer; 2012 Aug; 77(2):319-25. PubMed ID: 22483782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
    Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
    Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung].
    Sun PL; Liu JN; Cao LQ; Yao M; Gao HW
    Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):303-308. PubMed ID: 28468034
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.